Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutation
Shuji Murakami, Fumihiro Oshita, Makiko Sugiura…Volume:
71
Language:
english
DOI:
10.1007/s00280-012-2061-1
Date:
March, 2013
File:
PDF, 191 KB
english, 2013